DCM
IOVA icon

Delpha Capital Management’s Iovance Biotherapeutics IOVA Stock Holding History

Delpha Capital Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-833
Closed -$7K – 644
2017
Q4 		$7K Buy
+833
New +$6.69K 0.01% 1175

Other funds holding IOVA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Delpha Capital Management's IOVA Position: Q1 2018 in Review

Delpha Capital Management sold out of Iovance Biotherapeutics (IOVA) in Q1 2018, closing a stake of 833 shares — an estimated $7K sold.

Delpha Capital Management first reported a position in IOVA in Q4 2017 and held it in 1 quarter. The position peaked at $7K in Q4 2017. 122 funds tracked by Wall St. Rank hold IOVA as of Q1 2018.

  • Delpha Capital Management reported no remaining Iovance Biotherapeutics position as of Q1 2018 after selling out during the quarter.
  • Delpha Capital Management sold 833 Iovance Biotherapeutics shares in Q1 2018, an estimated $7K.
  • Delpha Capital Management first reported a position in Iovance Biotherapeutics in Q4 2017 and held it in 1 quarter.
  • Delpha Capital Management's Iovance Biotherapeutics position peaked at $7K in Q4 2017.
  • 122 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2018.

Based on Delpha Capital Management's 13F filing for Q1 2018, filed 11 May 2018.